Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer:a cross-sectional survey
- Author:
Ji Hyun KIM
1
;
Yumi LEE
;
Da-Young KIM
;
Sinae KIM
;
Sang-Soo SEO
;
Sokbom KANG
;
Sang-Yoon PARK
;
Myong Cheol LIM
Author Information
- Publication Type:Original Article
- From:Journal of Gynecologic Oncology 2024;35(1):e3-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objective:To identify the adherence rate to poly (ADP-ribose) polymerase (PARP) inhibitors and identify factors contributing to the deterioration of adherence at our institution.
Methods:The adherence rate to PARP inhibitors was calculated using self-reported Adherence to Refills and Medications Scale questionnaires from a cross-sectional survey. Multivariable logistic regression analysis was performed to identify the factors that affected adherence.
Results:Of the 131 respondents, 32 (24.4%) showed non-adherence to PARP inhibitors.In the multivariable logistic regression analysis, unemployed or retired status (odds ratio [OR]=4.878; 95% confidence interval [CI]=1.528–15.572; p=0.008), patients receiving niraparib (OR=3.387; 95% CI=1.283–8.940; p=0.014), and a lower score on the quality-oflife assessment (EORTC-QLQ-OV28), which reflects a better quality of life (QOC) with a lower symptom burden (OR=1.056; 95% CI=1.027–1.086; p<0.001) were associated with high adherence to PARP inhibitors.
Conclusion:Approximately one-fourth of patients with ovarian cancer are non-adherent to PARP inhibitors as maintenance treatment for newly diagnosed advanced ovarian cancer. The occupational status, type of PARP inhibitor, and QOC may affect adherence to PARP inhibitors.
